New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations
Chemotherapy for castration-resistant prostate cancer (CRPC) is only temporarily effective due to the onset of chemoresistance. We investigated the efficacy of NO- and H2S-releasing doxorubicins (NitDox and H2SDox) in overcoming drug resistance and evaluated their safety. New and innovative NO- and H2S-releasing doxorubicins (NitDox and H2SDox) showed a good intracellular accumulation and high cytotoxic activity in vitro in an androgen-independent and doxorubicin-resistant DU-145 prostate cancer cell line. Nude mice were subcutaneously injected with 4*106 DU-145 cells and treated once a week for 3 weeks with 5 mg/kg doxorubicin, NitDox, H2SDox or vehicle, i.p. Animal weight, tumor volume, intra-tumoral drug accumulation, apoptosis and the presence of nitrotyrosine and sulfhydryl (SH) groups within the tumor, were evaluated. Cardiotoxicity was assessed by measuring troponin plasma levels and the left ventricular wall thickness. In vivo, NitDox and H2SDox accumulated inside the tumors, significantly reduced tumor volumes by 60%, increased the percentage of apoptotic cells in both the inner and the outer parts of the tumors and the presence of nitrotyrosine and SH groups. Doxorubicin treatment was associated with reduced body weight and cardiotoxicity. On the contrary, NitDox and H2SDox were well tolerated and had a better safety profile. Combining efficacy with reduced cardiovascular side effects, NitDox and H2SDox are promising novel therapeutic agents for reversing chemoresistance in CRCP.
KeywordsCastration-resistant prostate cancer Doxorubicin P-glycoprotein p
The authors are very grateful to Prof. Piero Dolara for critical reading of the manuscript and his useful suggestions.
Compliance with ethical standards
Conflict of interest
Authors declare no conflicts of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All animal care and experimental protocols were approved by the Italian Ministry of Health with authorization number 49/2016-PR 21/01/2016.
- 1.Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2):245–256. https://doi.org/10.1016/j.cell.2009.04.056 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Castro E, Romero N, Olmos D (2014) State of the art treatment in castration resistant prostate cancer. EMJ Oncol 2:100–105 https://www.emjreviews.com/oncology/article/re-state-art-treatment-castration-resistant-prostate-cancer-forward-past/re-state-of-the-art-treatment-in-castration-resistant-prostate-cancer-forward-to-the-past-again/ Google Scholar
- 5.Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M (2014) National Comprehensive Cancer Network. Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12(5):686–718 http://www.jnccn.org/content/12/5/686.abstract?utm_source=TrendMD&utm_medium=cpc&utm_campaign=JNCCN_TrendMD_0 CrossRefGoogle Scholar
- 8.Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41:884–892. https://doi.org/10.1016/j.ctrv.2015.08.002 CrossRefPubMedGoogle Scholar
- 10.Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12(4):683–688. https://doi.org/10.1200/JCO.19126.96.36.1993 CrossRefPubMedGoogle Scholar
- 11.Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P, Kukreja RC (2010) Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 107(42):18202–18207. https://doi.org/10.1073/pnas.1006965107 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Shankaranarayanan JS, Kanwar JR, Al-Juhaishi AJ, Kanwar RK (2016) Doxorubicin conjugated to immunomodulatory anticancer Lactoferrin displays improved cytotoxicity overcoming prostate Cancer chemo resistance and inhibits tumour development in TRAMP mice. Sci Rep 6:32062. https://doi.org/10.1038/srep32062 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Chegaev K, Riganti C, Lazzarato L, Rolando B, Guglielmo S, Campia I, Fruttero R, Bosia A, Gasco A (2011) Nitric oxide donor – doxorubicin conjugates accumulate into doxorubicin resistant human colon cancer cells inducing cytotoxicity. ACS Med Chem Lett 2(7):494–497. https://doi.org/10.1021/ml100302t CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Chegaev K, Rolando B, Cortese D, Gazzano E, Buondonno I, Lazzarato L, Fanelli M, Hattinger CM, Serra M, Riganti C, Fruttero R, Ghigo D, Gasco A (2016) H2S-donating Doxorubicins may overcome cardiotoxicity and multidrug resistance. J Med Chem 59(10):4881–4889. https://doi.org/10.1021/acs.jmedchem.6b00184 CrossRefPubMedGoogle Scholar
- 21.Wong CC, Sagineedu SR, Sumon SH, Sidik SM, Phillips R, Lajis NH, Stanslas J. NCI in vitro and in silico anticancer screen, cell cycle pertubation and apoptosis-inducing potential of new acylated, benzylidene and isopropylidene derivatives of andrographolide. Environ Toxicol Pharmacol 38(2):489–501. https://doi.org/10.1016/j.etap.2014.07.016
- 22.Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A (2005) Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65(2):516–525 http://cancerres.aacrjournals.org/content/65/2/516.long PubMedGoogle Scholar
- 23.Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS (1997) Modulation of apoptosis by Sulindac, curcumin, Phenylethyl-3-methylcaffeate, and 6-Phenyihexyl Isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57:1301–1305 http://cancerres.aacrjournals.org/content/57/7/1301.long PubMedGoogle Scholar
- 25.Baggetto LG, Dong M, Bernaud J, Espinosa L, Rigal D, Bonvallet R, Marthinet E (1998) In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin. Biochem Pharmacol 1;56(9):1219–1228 https://www.sciencedirect.com/science/article/pii/S0006295298002299?via%3Dihub CrossRefGoogle Scholar
- 26.Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM, Gullino PM (1987) Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 47:4243–4247 http://cancerres.aacrjournals.org/content/47/16/4243.long PubMedGoogle Scholar
- 29.Bhangal G, Halford S, Wang J, Roylance R, Shah R, Waxman J (2000) Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 5(3):118–121 https://www.sciencedirect.com/science/article/pii/S1078143999000551?via%3Dihub CrossRefPubMedGoogle Scholar
- 30.Sharom FJ (2011) Multidrug resistance protein (P-glycoprotein; MDR1). Biochemical Society Essays Biochem 50:161–178 https://pdfs.semanticscholar.org/d6eb/ca84e778bbbd34fcaf069db9d54c65f99c9b.pdf CrossRefGoogle Scholar
- 32.Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F, ESMO Guidelines Working Group (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol Suppl 7:155–66. https://doi.org/10.1093/annonc/mds293
- 35.Chegaev K, Fraix A, Gazzano E, Abd-Ellatef GE, Blangetti M, Rolando B, Conoci S, Riganti C, Fruttero R, Gasco A, Sortino S (2017) Light-regulated NO release as a novel strategy to overcome doxorubicin multidrug resistance. ACS Med Chem Lett 8(3):361–365. https://doi.org/10.1021/acsmedchemlett.7b00016 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circ 109:2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC CrossRefGoogle Scholar
- 39.Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S (2014) Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol 4:277. https://doi.org/10.3389/fonc.2014.00277 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L (2011) Dietary nitrate supplementation protects against doxorubicin-induced cardiomyopathy by improving mitochondrial function. J Am Coll Cardiol 57(21):2181–2189. https://doi.org/10.1016/j.jacc.2011.01.024 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Su YW, Liang C, Jin HF, Tang XY, Han W, Chai LJ, Zhang CY, Geng B, Tang CS, Du JB (2009) Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circ J 73(4):741–749 https://www.jstage.jst.go.jp/article/circj/73/4/73_CJ-08-0636/_article CrossRefPubMedGoogle Scholar
- 46.Liu MH, Lin XL, Zhang Y, He J, Tan TP, Wu SJ, Liu J, Tian W, Chen L, Yu S, Li J, Yuan C (2015) Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1/2 in H9c2 cardiac myocytes. Mol Med Rep 12:6841–6848. https://doi.org/10.3892/mmr.2015.4234 CrossRefPubMedGoogle Scholar
- 48.Wang XY, Yang CT, Zheng DD, Mo LQ, Lan AP, Yang ZL, Hu F, Chen PX, Liao XX, Feng JQ (2012) Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem 363:419–426. https://doi.org/10.1007/s11010-011-1194-6 CrossRefPubMedGoogle Scholar